par Bisilliat Donnet, Charlotte 
;Acolty, Valérie ;Azouz, Abdulkader ;Taquin, Anaëlle ;Henin, Coralie ;Cafarello, Sarah Trusso;Denanglaire, Sébastien ;Mazzone, Massimiliano;Oldenhove, Guillaume ;Leo, Oberdan ;Goriely, Stanislas ;Moser, Muriel
Référence Cancer immunology research, 11, 3, page (339-350)
Publication Publié, 2023-03-01
;Acolty, Valérie ;Azouz, Abdulkader ;Taquin, Anaëlle ;Henin, Coralie ;Cafarello, Sarah Trusso;Denanglaire, Sébastien ;Mazzone, Massimiliano;Oldenhove, Guillaume ;Leo, Oberdan ;Goriely, Stanislas ;Moser, Muriel Référence Cancer immunology research, 11, 3, page (339-350)
Publication Publié, 2023-03-01
Article révisé par les pairs
| Résumé : | The prolyl hydroxylase domain/hypoxia-inducible factor (PHD/HIF) pathway has been implicated in a wide range of immune and inflammatory processes, including in the oxygen-deprived tumor microenvironment. To examine the effect of HIF stabilization in antitumor immunity, we deleted Phd2 selectively in T lymphocytes using the cre/lox system. We show that the deletion of PHD2 in lymphocytes resulted in enhanced regression of EG7-OVA tumors, in a HIF-1α-dependent manner. The enhanced control of neoplastic growth correlated with increased polyfunctionality of CD8+ tumor-infiltrating lymphocytes, as indicated by enhanced expression of IFNγ, TNFα, and granzyme B. Phenotypic and transcriptomic analyses pointed to a key role of glycolysis in sustaining CTL activity in the tumor bed and identified the PHD2/HIF-1 pathway as a potential target for cancer immunotherapy. |
